Table 1 Clinico-pathological characteristics of the study cohort. Group 1 and Group 2 are the two groups of HR + /HER2− patients described below. Statistical significance was determined using Student's t-test or Pearson's chi-squared test
From: Clustering of HR + /HER2− breast cancer in an Asian cohort is driven by immune phenotypes
Overall | Group 1 | Group 2 | Statistical Significance | |
|---|---|---|---|---|
Subjects (n) | 934 | 61 | 421 | |
Patient age (Mean ± SD) | 53.78 ± 11.65 | 50.56 ± 10.08 | 54.16 ± 11.89 | 0.0247 |
Clinical subtypes (n(%)) | ||||
HR−/HER2 + | 138 (14.78) | 5 (8.20) | 5 (1.19) | 0.0004 |
HR + /HER2− | 432 (46.25) | 39 (63.93) | 312 (74.11) | |
HR + /HER2 + | 126 (13.49) | 10 (16.39) | 60 (14.25) | |
TNBC | 159 (17.02) | 4 (6.56) | 7 (1.66) | |
N/A | 79 (8.46) | 3 (4.92) | 37 (8.79) | |
TNM Stage (n(%)) | ||||
0 | 23 (2.46) | 2 (3.28) | 8 (1.90) | 0.7430 |
I | 146 (15.63) | 8 (13.11) | 67 (15.91) | |
II | 428 (45.82) | 28 (45.90) | 198 (47.03) | |
III | 270 (28.91) | 20 (32.79) | 114 (27.08) | |
IV | 40 (4.28) | 2 (3.28) | 24 (5.70) | |
N/A | 27 (2.89) | 1 (1.64) | 10 (2.38) | |
Grade (n(%)) | ||||
1 | 27 (2.87) | 3 (4.92) | 22 (5.23) | 0.3310 |
2 | 385 (40.45) | 31 (50.82) | 248 (58.91) | |
3 | 420 (44.46) | 22 (36.07) | 113 (26.84) | |
N/A | 102 (12.22) | 5 (8.20) | 38 (9.03) | |
Histology (n(%)) | ||||
Ductal carcinoma | 800 (85.65) | 48 (76.19) | 361 (82.23) | < 0.0001 |
Lobular carcinoma | 30 (3.21) | 11 (17.46) | 11 (2.51) | |
Other | 1 (0.11) | 0 (0.00) | 0 (0.00) | |
N/A | 103 (11.03) | 2 (3.17) | 49 (11.16) | |